Patents by Inventor Andrew Xian Chen
Andrew Xian Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170056326Abstract: The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same.Type: ApplicationFiled: November 10, 2016Publication date: March 2, 2017Inventors: Hailiang Chen, Andrew Xian Chen, Dushyanth Surakanti, Franklin Okumu
-
Patent number: 9522169Abstract: The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same.Type: GrantFiled: July 7, 2015Date of Patent: December 20, 2016Assignee: Dr. Reddy's Laboratories Ltd.Inventors: Hailiang Chen, Andrew Xian Chen, Dushyanth Surakanti, Franklin Okumu
-
Patent number: 9517202Abstract: The present invention is directed to phospholipid compositions and methods of preparation of phospholipid depots that are injectable through a fine needle. The phospholipid depots prepared by the methods described herein comprise nanometer-sized phospholipid particles and exhibit a higher degree of structural order compared to compositions prepared by other methods.Type: GrantFiled: June 14, 2012Date of Patent: December 13, 2016Assignee: LATITUDE PHARMACEUTICALS INC.Inventors: Andrew Xian Chen, Hailiang Chen
-
Publication number: 20160354390Abstract: Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.Type: ApplicationFiled: August 18, 2016Publication date: December 8, 2016Applicant: Dr. Reddy's Laboratories Ltd.Inventors: Franklin Okumu, Jan-Jon Chu, Julie Ann Webb, Rafael Anthony Sabino, Andrew Xian Chen
-
Patent number: 9446056Abstract: Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.Type: GrantFiled: February 11, 2015Date of Patent: September 20, 2016Assignee: Dr. Reddy's Laboratories Ltd.Inventors: Franklin Okumu, Jan-Jon Chu, Julie Ann Webb, Rafael Anthony Sabino, Andrew Xian Chen
-
Patent number: 9375402Abstract: The invention is directed to formulations of bioactive compounds of limited water solubility, inhibitors of focal adhesion kinase (FAK) of the 2,4-diaminopyridine class, adapted for oral administration to patients. The formulations are self-emulsifying in the gastrointestinal tract of the patients, providing enhanced absorption and bioavailability of the bioactive compounds as dispersions or emulsions in an oil base. For example, esters of PEG-ylated glycerol can be used as the oil, in conjunction with surfactants such as lecithin and TEPG succinate and solubilizers such as PEG 400 to provide useful oral formulations for administration to patients having a malcondition wherein inhibition of FAK is medically indicated, such as cancer or arthritis.Type: GrantFiled: August 14, 2013Date of Patent: June 28, 2016Assignee: VERASTEM, INC.Inventors: Andrew Xian Chen, Yali J. Tsai
-
Patent number: 9370486Abstract: In certain embodiments, this invention sets forth compositions, methods, and uses regarding a nanoemulsion composition that comprises a fat-soluble vitamin K and can therapeutically replace Phytonadione Injectable Emulsion, USP.Type: GrantFiled: November 28, 2012Date of Patent: June 21, 2016Assignee: LATITUDE PHARMACEUTICALS INC.Inventor: Andrew Xian Chen
-
Patent number: 9248098Abstract: The present invention relates to a pharmaceutical composition comprising spicamycin derivatives that vary in their fatty acid side chain moieties and are useful in the treatment of pain. The invention further provides a method of using the pharmaceutical composition to treat pain, including neuropathic pain.Type: GrantFiled: October 9, 2009Date of Patent: February 2, 2016Assignee: DARA BIOSCIENCES, INC.Inventors: John R. Didsbury, Kenneth J. Ingold, Linda Goff Jet, Andrew Xian Chen, Hailiang Chen
-
Publication number: 20150306173Abstract: The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same.Type: ApplicationFiled: July 7, 2015Publication date: October 29, 2015Inventors: Hailiang Chen, Andrew Xian Chen, Dushyanth Surakanti, Franklin Okumu
-
Patent number: 9132144Abstract: The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same.Type: GrantFiled: September 23, 2011Date of Patent: September 15, 2015Assignee: Dr. Reddy's Laboratories Ltd.Inventors: Hailiang Chen, Andrew Xian Chen, Dushyanth Surakanti, Franklin Okumu
-
Publication number: 20150224121Abstract: Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.Type: ApplicationFiled: February 11, 2015Publication date: August 13, 2015Applicant: Dr. Reddy's Laboratories Ltd.Inventors: Franklin Okumu, Jan-Jon Chu, Julie Ann Webb, Rafael Anthony Sabino, Andrew Xian Chen
-
Publication number: 20140378381Abstract: The present invention provides an oil-in-water nanoemulsion containing glucagon, an oily phase, and an aqueous phase, wherein the glucagon is physically and chemically stable and the nanoemulsion is suitable for administration by manual injection or by a pump to treat hypoglycemia.Type: ApplicationFiled: June 25, 2014Publication date: December 25, 2014Inventors: Andrew Xian Chen, Norman Keith Orida, Hailiang Chen, Hau Huu Dang
-
Patent number: 8877746Abstract: Compositions and methods of making the same for in vivo delivery of lixivaptan to a subject in need thereof are described. The composition includes a substantially water-insoluble pharmacologically active agent (e.g., lixivaptan) and a substantially water-insoluble matrix forming material (e.g., a Vitamin E semi-ester), wherein the pharmacologically active agent is dispersed in said matrix forming material, and wherein the composition delivers said substantially water-insoluble pharmacologically active agent upon exposure to physiological medium.Type: GrantFiled: August 24, 2010Date of Patent: November 4, 2014Assignee: Cardioklne, IncInventors: Hailiang Chen, Andrew Xian Chen, Patricia Frech, Khawla Abu-Izza, Christoph Schmidt
-
Publication number: 20140275261Abstract: The present application provides parenteral compositions of diclofenac or its pharmaceutically acceptable salt and methods for making and using such compositions. Some of the compositions of the present application has one or more following properties: (1) ready to be injectable, (2) in the form of an oil-water emulsion, (3) stable under appropriate storage conditions, (4) containing therapeutically effective amount of diclofenac or its pharmaceutically acceptable salt, (5) sterilizable by filtration (6) containing components acceptable by regulatory agencies (e.g. the FDA), (7) containing low oil content and thus not exacerbating hyperlipidemia, and (8) is neither hypoallergenic nor vein irritating.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: DR. REDDY'S LABORATORIES, INC.Inventors: Franklin Okumu, Andrew Xian Chen, Hailiang Chen
-
Publication number: 20140249077Abstract: The present invention is directed to compositions and methods of preparation of phospholipid gels.Type: ApplicationFiled: June 8, 2012Publication date: September 4, 2014Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLCInventors: Andrew Xian Chen, Hailiang Chen
-
Publication number: 20140206692Abstract: The invention is directed to formulations of bioactive compounds of limited water solubility, inhibitors of focal adhesion kinase (FAK) of the 2,4-diaminopyridine class, adapted for oral administration to patients. The formulations are self-emulsifying in the gastrointestinal tract of the patients, providing enhanced absorption and bioavailability of the bioactive compounds as dispersions or emulsions in an oil base. For example, esters of PEG-ylated glycerol can be used as the oil, in conjunction with surfactants such as lecithin and TEPG succinate and solubilizers such as PEG 400 to provide useful oral formulations for administration to patients having a malcondition wherein inhibition of FAK is medically indicated, such as cancer or arthritis.Type: ApplicationFiled: August 14, 2013Publication date: July 24, 2014Inventors: Andrew Xian Chen, Yali J. Tsai
-
Publication number: 20140155320Abstract: The present invention provides a method of preventing and/or treating a wound infection by introducing to a wound a clear depot comprising a hydrophilic water-soluble pharmaceutically active agent(s) selected from the group consisting of vancomycin, gentamicin, and a mixture thereof, water, a phospholipid, an oil, a pH adjusting agent, and a viscosity modifying agent, wherein the water present in the viscous depot is no more than about 4 wt %, no more than about 2 wt %, or no more than about 0.5 wt % of water relative to the total weight of the depot.Type: ApplicationFiled: October 18, 2011Publication date: June 5, 2014Applicant: DR. REDDY'S LABORATORIES, INC.Inventors: Hailiang Chen, Andrew Xian Chen, Dushyanth Surakanti, Franklin Omuku
-
Patent number: 8697746Abstract: A solid dispersion comprising ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester made amorphous in the presence of a water-soluble cellulosic polymer has improved storage stability. The solid dispersion also has improved solubility for an improved bioavailability.Type: GrantFiled: July 13, 2011Date of Patent: April 15, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Andrew Xian Chen, John Fan, Masazumi Yamaguchi
-
Patent number: 8557861Abstract: The present invention provides injectable oil-in-water emulsions of taxoid drugs or other water insoluble drugs. The present invention also provides methods for preparing and using such oil-in-water emulsions.Type: GrantFiled: September 28, 2004Date of Patent: October 15, 2013Assignee: Mast Therapeutics, Inc.Inventor: Andrew Xian Chen
-
Patent number: 8470346Abstract: The present invention provides antiviral compositions that comprise one or more of an ionic multivalent metal component, a cationic polymer, and a cationic surfactant. The present invention also provides methods for making and using such antiviral compositions.Type: GrantFiled: May 19, 2011Date of Patent: June 25, 2013Assignee: Mast Therapeutics, Inc.Inventor: Andrew Xian Chen